Drug Discovery

Regeneron plans $1.8bn investment to expand research facilities in New York, US

Regeneron has announced plans to invest about $1.8bn to expand its facilities at its Westchester County campus in the US, over the next six years.

Novo Nordisk to acquire Prothena’s ATTR amyloidosis programme for $1.2bn

Danish pharma company Novo Nordisk has agreed to acquire Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis programme for a deal valued at $1.2bn.

Altesa signs license agreement with Vaxart for Vapendavir antiviral

Altesa Biosciences has signed an exclusive worldwide license agreement with biotechnology firm Vaxart for the development and commercialisation of the latter’s patented formulation of the capsid-binding Vapendavir antiviral.

Eureka and MSK sign license agreement with Sanofi for GPRC5D binder

Eureka Therapeutics and Memorial Sloan Kettering Cancer Center (MSK) have signed a new G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) license agreement with Sanofi to target multiple myeloma.

GSK, Alector to co-develop antibodies for neurodegenerative diseases

GlaxoSmithKline (GSK) and Alector have partnered to co-develop and commercialise two clinical stage monoclonal antibodies for neurodegenerative diseases.

Sanofi establishes mRNA Center of Excellence to accelerate Covid-19 vaccines development

Global biopharmaceutical firm Sanofi has launched a dedicated vaccines mRNA Center of Excellence to accelerate development and delivery of next-generation vaccines.

AbbVie to acquire TeneoOne and multiple myeloma drug from Teneobio

AbbVie is set to acquire Teneobio affiliate TeneoOne and its lead drug candidate TNB-383B, which is being developed to treat relapsed or refractory multiple myeloma (R/R MM).

ViiV Healthcare, Halozyme partner to develop HIV medicines

ViiV Healthcare has signed a global collaboration and license agreement with Halozyme Therapeutics to develop “ultra-long-acting” medicines for HIV.

Arrowhead, Horizon sign collaboration deal for RNAi therapeutic development

Arrowhead Pharmaceuticals has signed a global collaboration and license agreement with Horizon Therapeutics for the development of RNA interference (RNAi) therapeutic, ARO-XDH.